Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Abstract Background Pediatric-type diffuse high-grade glioma (pHGG) is the most frequent malignant brain tumor in children and can be subclassified into multiple entities. Fusion genes activating the MET receptor tyrosine kinase often occur in infant-type hemispheric glioma (IHG) but also in other p...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Marc Zuckermann, Chen He, Jared Andrews, Aditi Bagchi, Roketa Sloan-Henry, Brandon Bianski, Jia Xie, Yingzhe Wang, Nathaniel Twarog, Arzu Onar-Thomas, Kati J. Ernst, Lei Yang, Yong Li, Xiaoyan Zhu, Jennifer K. Ocasio, Kaitlin M. Budd, James Dalton, Xiaoyu Li, Divyabharathi Chepyala, Junyuan Zhang, Ke Xu, Laura Hover, Jordan T. Roach, Kenneth Chun-Ho Chan, Nina Hofmann, Peter J. McKinnon, Stefan M. Pfister, Anang A. Shelat, Zoran Rankovic, Burgess B. Freeman, Jason Chiang, David T. W. Jones, Christopher L. Tinkle, Suzanne J. Baker
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMC 2024-06-01
Reeks:	Molecular Cancer
Onderwerpen:	Combination therapy Pediatric-type diffuse high-grade glioma Radiosensitization MET inhibition Preclinical trials Capmatinib
Online toegang:	https://doi.org/10.1186/s12943-024-02027-6
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!